News

ICYMI: Denise Visco, MD, shares the take-home message from her 2019 ASCRS presentation.

A new therapy is being investigated in a phase IIb trial to test its safety and effectiveness in patients with moderate-to-severe dry eye disease.

Phase III studies of a gene therapy for Leber Hereditary Optic Neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data.

Tools for higher-order OCT assessment enable evaluation of features of interest, such as targeted retinal layers or fluid compartments, and may allow for unique characterization of disease phenotypes and treatment response.

OCT-A detected microcirculatory disturbances during acute post-aural migraine attacks may be an important tool in elucidating the pathophysiological relationship between migraine, aura, and ischemia.